OncoCyte Corp (OCX) Peer Comparison

$2.83

$-0.33 (-10.44%)

As on 17-Jul-2025 09:30EDT

Market cap

$92 Mln

Revenue (TTM)

$4 Mln

P/E Ratio

--

P/B Ratio

7.9

Div. Yield

0 %

Edit

	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)	Blueprint Medicines Corp (BPMC)
Market cap ($ Mln)	92	54	8,372
Revenue ($ Mln)	4	9	562
Net Profit ($ Mln)	-58.21	-64.49	-155.73
Net Margin (%)	-1,514.57	-701.53	-27.70
RoE (%)	-584.12	-67.54	-47.53
Price to Earnings	--	--	--
Price-To-Book	7.92	0.67	24.44

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)	Blueprint Medicines Corp (BPMC)
Operating Revenue	3.84	9.19	562.12
Cost of Revenue	1.44	0.83	23.39
Gross Profit	0.74	9.85	488.66
Operating Expenses	60.81	79.53	713.04
Operating Profit (EBIT)	-58.57	-70.34	-174.31
Other Income	0.00	0.00	0.00
Profit before Tax	-58.21	-64.49	-153.89
Provision for Tax	0.00	0.00	1.84
Profit after Tax (Net Income)	-58.21	-64.49	-155.73
Minority Interest	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00

Liabilities ($ Mln)

	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)	Blueprint Medicines Corp (BPMC)
Shareholder's Funds	10.22	79.81	342.13
Minority Interest	0.00	0.00	0.00
Non-Current Liabilities	40.46	20.45	602.89
Current Liabilities	9.68	7.88	250.58
Total Liabilities	35.08	124.36	1,179.81

Assets ($ Mln)

	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)	Blueprint Medicines Corp (BPMC)
Non-Current Assets	24.10	6.27	493.54
Current Assets	36.26	101.87	702.07
Total Assets	35.08	124.36	1,179.81
Total Debt*	3.48	24.09	122.75
Net Current Assets	26.58	93.99	451.49

Cashflow ($ Mln)

	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)	Blueprint Medicines Corp (BPMC)
Cash From Operating Activities	-20.71	-65.44	-192.59
Cash Flow from Investing Activities	--	85.44	-47.50
Cash from Financing Activities	20.43	0.25	273.11
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)	Blueprint Medicines Corp (BPMC)
ROCE (%)	-611.12	-57.42	-10.09
ROE (%)	-584.12	-67.54	-47.53
ROA (%)	-77.95	-40.55	-11.57
EBIT Margin (%)	-1,349.41	-550.46	-19.26
Net Margin (%)	-1,514.57	-701.53	-27.70
Cash Profit Margin (%)	0.00	0.00	0.00

Growth Ratios

	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)	Blueprint Medicines Corp (BPMC)
Revenue Growth (%)	178.08	21.15	99.19
EBIT Growth (%)	-157.26	53.53	74.53
Net Profit Growth (%)	-45.72	44.60	45.98
EPS Growth (%)	--	46.44	48.84
Book Value Growth (%)	--	-42.96	10.47

Valuation Ratios

	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)	Blueprint Medicines Corp (BPMC)
Price / Earnings	--	-0.67	-82.06
Price / Book Value	--	0.65	18.43
Dividend Yield (%)	--	--	--
EV/EBITDA	0.08	0.49	260.78
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)	Blueprint Medicines Corp (BPMC)
Debt to Equity	0.00	0.00	1.01
Short term debt to equity ratio	0.14	0.05	0.17
Current Ratio	3.75	12.93	2.80
Quick Ratio	3.70	12.93	2.75
Interest Coverage	-592.93	-13.30	-1.49

Operating Efficiency Ratios

	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)	Blueprint Medicines Corp (BPMC)
Debtors to sales (%)	92.12	0.00	14.20
Asset Turnover	0.05	0.06	0.42
Receivable days	203.60	--	43.35
Inventory Days	65.62	--	315.51
Payable days	517.30	140.96	104.16
Cash Conversion Cycle	-248.08	--	254.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly